---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-084650"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2025-06-11T23:59:59+00:00"
generated_at: "2026-05-19T13:23:40.309579+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Iterum Therapeutics enters commercialization agreement with EVERSANA for ORLYNVAH in US

## Summary
- Eversana will be exclusive provider of sales, marketing, logistics, regulatory, and medical affairs services for ORLYNVAH.
- ITUS retains legal, regulatory, manufacturing, and books sales; pays fees and expenses per statements of work.
- Term is 5 years from commercial launch; either party can terminate for material breach, insolvency, or certain law changes.
- ITUS or change-of-control counterparty may terminate upon paying specified fees; Eversana can terminate if ORLYNVAH is withdrawn.
- Agreement includes customary confidentiality, indemnification, and liability limitations.

## SEC filing metadata
- accession: 0000950170-25-084650
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2025-06-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017025084650/0000950170-25-084650-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017025084650/itrm-20250606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-084650
- JSON: https://secwatch.observer/filing/0000950170-25-084650.json
- Plain text: https://secwatch.observer/filing/0000950170-25-084650.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.